This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Oncopeptides Past Earnings Performance
Past criteria checks 0/6
Oncopeptides has been growing earnings at an average annual rate of 13.3%, while the Biotechs industry saw earnings growing at 15.5% annually. Revenues have been growing at an average rate of 24.5% per year.
Key information
13.27%
Earnings growth rate
22.45%
EPS growth rate
Biotechs Industry Growth
17.04%
Revenue growth rate
24.50%
Return on equity
n/a
Net Margin
-627.53%
Next Earnings Update
14 Aug 2024
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Oncopeptides makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:ONPP.F Revenue, expenses and earnings (SEK Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 24
39
-246
189
105
31 Dec 23
35
-249
188
107
30 Sep 23
30
-259
178
131
30 Jun 23
27
-307
178
175
31 Mar 23
9
-310
154
182
31 Dec 22
8
-338
142
218
30 Sep 22
-14
-641
304
345
30 Jun 22
41
-1,330
464
444
31 Mar 22
99
-1,294
681
567
31 Dec 21
118
-1,430
874
680
30 Sep 21
140
-1,549
907
727
30 Jun 21
86
-1,155
889
771
31 Mar 21
19
-1,532
788
831
31 Dec 20
0
-1,595
654
866
30 Sep 20
0
-1,327
494
792
30 Jun 20
0
-1,133
364
750
31 Mar 20
0
-904
262
655
31 Dec 19
0
-741
199
548
30 Sep 19
0
-608
146
482
30 Jun 19
0
-512
116
399
31 Mar 19
0
-485
124
366
31 Dec 18
0
-411
106
314
30 Sep 18
0
-368
100
276
30 Jun 18
0
-325
80
255
31 Mar 18
0
-248
47
205
31 Dec 17
0
-250
50
198
30 Sep 17
0
-243
52
180
30 Jun 17
0
-216
53
152
31 Mar 17
0
-172
38
124
31 Dec 16
0
-125
25
90
31 Dec 15
0
-62
10
44
Quality Earnings: ONPP.F is currently unprofitable.
Growing Profit Margin: ONPP.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ONPP.F is unprofitable, but has reduced losses over the past 5 years at a rate of 13.3% per year.
Accelerating Growth: Unable to compare ONPP.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ONPP.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.8%).
Return on Equity
High ROE: ONPP.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2024/07/31 01:15
End of Day Share Price
2024/05/03 00:00
Earnings
2024/03/31
Annual Earnings
2023/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncopeptides AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.